Online Measurement of Cognitive functioning in patients with cancers with CNS involvement

Published: 20-07-2022
Last updated: 06-04-2024

Primary Objective: To test the feasibility of online neuropsychological assessments using the Amsterdam Cognition Scan (ACS) compared to classical neuropsychological assessments in patients with cancers with CNS involvement.

Ethical review	Approved WMO
Status	Pending
Health condition type	Metastases
Study type	Observational non invasive

Summary

ID

NL-OMON51344

Source
ToetsingOnline

Brief title
OMCog-CNS

Condition

- Metastases
- Structural brain disorders

Synonym
Cognitive deficits, memory and concentration problems

Research involving
Human

Sponsors and support

Primary sponsor: Antoni van Leeuwenhoek Ziekenhuis
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: cancer, central nervous system, cognitive functioning, online

Outcome measures

Primary outcome

We will calculate completion rates for the classical neuropsychological test outcomes and for the ACS test outcomes. The completion rate for each test outcome of the ACS, is considered acceptable when at most 10% lower than the completion rate of the equivalent classical neuropsychological test.

Secondary outcome

n.a.

Study description

Background summary

Cognitive testing with classical neuropsychological assessments is time-consuming and labor-intensive for patients and test administrators. Online testing of cognitive functioning offers an attractive alternative to collect cognitive data for research purposes and for monitoring and exploring cognitive functioning in clinical settings. The Amsterdam Cognition Scan (ACS) is an online neuropsychological test battery that was designed to measure the same cognitive constructs as classical neuropsychological tests. We have extensively tested and evaluated the ACS in patients who have cancers without central nervous system (CNS) involvement and healthy controls. Currently, the ACS is used in 15 clinical trials and normative data have been acquired in 600 healthy controls. In these populations, we have shown that assessing cognitive functioning with the ACS is highly feasible and its psychometric properties are comparable to classical neuropsychological assessments. However, because cognitive impairments (including motor impairments) are often more severe in patients with cancers with CNS involvement than those who have cancers without CNS involvement, we now aim to evaluate the feasibility of administering the ACS in patients with brain metastases. Because the ACS is designed for unsupervised assessment (e.g., at the patient*s home), we will administer the ACS onsite mimicking unsupervised assessment, but in the presence of a test administrator to observe the patients. This will allow us to formulate, if

necessary, recommendations for adaptation of the ACS to enable unsupervised administration of the ACS in patients with cancers with CNS involvement.

Study objective

Primary Objective: To test the feasibility of online neuropsychological assessments using the Amsterdam Cognition Scan (ACS) compared to classical neuropsychological assessments in patients with cancers with CNS involvement.

Study design

Observational study. Within subject design. Order of classical and online test battery counterbalanced. One session

Study burden and risks

Taking part in the study takes time, and some neuropsychological tests can be difficult. This can sometimes be experienced as a disadvantage. There are no risks associated with participation.

Contacts

Public
Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121
Amsterdam 1066 CX
NL
Scientific
Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121
Amsterdam 1066 CX
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients diagnosed with >= 1 brain metastases
Scheduled for, or treated with stereotactic radiotherapy
Age range 18-89

Exclusion criteria

Insufficient command of the Dutch language

Study design

Design

Study type: Observational non invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Other

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	19-04-2022
Enrollment:	100
Type:	Anticipated

Ethics review

Approved WMO

Date:	20-07-2022
Application type:	First submission
Review commission:	METC NedMec

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL80205.031.22